TSE:4523Pharmaceuticals
How Investors Are Reacting To Eisai (TSE:4523) Leaning On Leqembi After Fresh Sales Update
Eisai Co., Ltd. recently reported preliminary first-quarter 2026 sales of ¥26.2 billion, alongside fiscal 2025 revenue of ¥88 billion from its Alzheimer’s drug Leqembi, underscoring the scale of its neurology operations.
This combination of strong Leqembi revenue and fresh quarterly sales data highlights how Eisai’s neuroscience focus is increasingly anchored by a single high-impact Alzheimer’s therapy.
Next, we’ll examine how Leqembi’s ¥88 billion revenue contribution and the latest...